文献速递造血干细胞移植与细胞治疗

IL2RG/JAK3严重联合免疫缺陷患者造血干细胞移植后B细胞分化及IL-21应答

B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.
PubMed 文献 · Blood · 2018-05-04

该研究分析了48例移植后超过2年的IL2RG/JAK3严重联合免疫缺陷患者,供者均非同胞相合。滤泡辅助性T细胞发育动力学与健康幼儿相似,B细胞体外分化为浆母细胞及免疫球蛋白分泌对IL-21的应答与是否使用预处理、供者B细胞植入、是否脱离免疫球蛋白替代治疗及破伤风疫苗应答强相关。

要点

  • 滤泡辅助性T细胞发育动力学与健康幼儿相似,B细胞功能差不能归因于滤泡辅助性T细胞发育失败。
  • B细胞对IL-21的体外分化与免疫球蛋白分泌应答与预处理使用、供者B细胞植入、脱离免疫球蛋白替代及破伤风疫苗应答强相关。
  • 接受免疫球蛋白替代且血清IgM正常者,其B细胞对IL-21的体外应答与低血清IgM者相似,均较差。

核心结论

  • IL2RG/JAK3严重联合免疫缺陷患者移植后B细胞对IL-21的体外应答可能预测临床相关的体液免疫功能。

研究设计与样本

  • 分析48例移植后年龄大于2岁、供者非同胞相合的IL2RG/JAK3严重联合免疫缺陷患者。

主要发现

  • 滤泡辅助性T细胞在这些患者中发育,动力学与健康幼儿相似。
  • B细胞体外分化为浆母细胞及免疫球蛋白分泌对IL-21的应答与预处理使用、供者B细胞植入、脱离免疫球蛋白替代治疗及破伤风疫苗应答强相关。
  • 接受免疫球蛋白替代且血清IgM正常的患者,其B细胞对IL-21的体外应答差,与低血清IgM者相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplant (HSCT) typically results in donor T-cell engraftment and function in patients with severe combined immunodeficiency (SCID), but humoral immunity, particularly when using donors other than matched siblings, is variable. B-cell function after HSCT for SCID depends on the genetic cause, the use of pre-HSCT conditioning, and whether donor B-cell chimerism is achieved. Patients with defects in IL2RG or JAK3 undergoing HSCT without conditioning often have poor B-cell function post-HSCT, perhaps as a result of impairment of IL-21 signaling in host-derived B cells. To investigate the effect of pre-HSCT conditioning on B-cell function, and the relationship of in vitro B-cell function to clinical humoral immune status, we analyzed 48 patients with IL2RG/JAK3 SCID who were older than 2 years after HSCT with donors other than matched siblings. T follicular helper cells (TFH) developed in these patients with kinetics similar to healthy young children; thus, poor B-cell function could not be attributed to a failure of TFH development. In vitro differentiation of B cells into plasmablasts and immunoglobulin secretion in response to IL-21 strongly correlated with the use of conditioning, donor B-cell engraftment, freedom from immunoglobulin replacement, and response to tetanus vaccine. Patients receiving immunoglobulin replacement who had normal serum immunoglobulin M showed poor response to IL-21 in vitro, similar to those with low serum IgM. In vitro response of B cells to IL-21 may predict clinically relevant humoral immune function in patients with IL2RG/JAK3 SCID after HSCT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Miggelbrink AM, Logan BR, Buckley RH, et al. B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood. 2018. PMID: 29728406. doi:10.1182/blood-2017-10-809822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。